Last reviewed · How we verify
Seasonal affective disorder — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Wellbutrin | bupropion | GSK (GlaxoSmithKline) | NDRI (Norepinephrine-dopamine reuptake inhibitor) | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor | 1985-12-30 | |
| Wellbutrin | Wellbutrin | Mclean Hospital | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor | |||
| Elontril | Elontril | Boehringer Ingelheim | Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Boehringer Ingelheim · 1 drug in Seasonal affective disorder
- GSK (GlaxoSmithKline) · 1 drug in Seasonal affective disorder
- Mclean Hospital · 1 drug in Seasonal affective disorder
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Seasonal affective disorder:
- Seasonal affective disorder treatment updates — RSS
- Seasonal affective disorder treatment updates — Atom
- Seasonal affective disorder treatment updates — JSON
Cite this brief
Drug Landscape (2026). Seasonal affective disorder — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seasonal-affective-disorder. Accessed 2026-06-10.
Related
- Seasonal affective disorder full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing